Author, year [ref] | Study design | Severity score | Observation period | Intervention | Conversion rate | Hospital mortality (%) | ||
---|---|---|---|---|---|---|---|---|
Balser JR, 1998 [58] | Randomized controlled | APACHE III | 59 | Within 2 h | Esmolol | 59.1% [20/34] | p = 0.067 | 31 |
65 | Diltiazem | 27.3% [6/22] | 38 | |||||
Seguin P, 2006 [51] | Prospective observational | SAPS II | 47 | 10 ± 10 h | DC | 100% [3/3] | NA | 31.2 |
Amiodarone | 100% [4/4] | |||||||
Digoxin | 100% [1/1] | |||||||
No intervention | 100% [4/4] | |||||||
Sleeswijk ME, 2008 [59] | Prospective observational | APACHE II | 19 | Within 24Â h | MgSO4-amiodarone step-up scheme | 93.1% [27/29] | NA | 37.9 |
Meierhenrich R, 2010 [53] | Prospective observational | SAPS II | 31a | NA | DC (17/49) | 85.7% [42/49]c | NA | 48ad |
34b | Amiodarone (36/49) | 23bd | ||||||
Digitalis (31/49) | ||||||||
β-Blockers (25/49) | ||||||||
Kanji S, 2012 [55] | Retrospective observational | APACHE II | 22.6 | Within 24Â h | DCe | 26.9% [7/26] | NA | 32 |
Amiodaronef | 87.4% [90/103] | |||||||
Sotalol | 100% [2/2] | |||||||
Rate control | 75% [21/28] |